Abstract
Purpose
The usefulness of fluorine 18 fluorodeoxyglucose (18F-FDG) imaging in differentiated thyroid cancer (DTC) has been demonstrated by investigators.
The aim of this study is to compare the ability of fluorodeoxyglucose (FDG)-single
photon emission computed tomography (SPECT) to detect metastatic DTC with posttherapeutic
iodine131 (131I) scintigraphy.
Methods
239 patients (78 men, 161 women; age range, 23–76 years, mean 45 years); All patients
underwent FDG-SPECT and 131I whole-body scan.
Results
The sensitivity of 18F-FDG and 131I imaging in the patients with high hTg levels is 48.7% (114/234) and 50.4% (118/234)
respectively. However, the combined sensitivity of both protocols is 89.7% (210/234).
In the patients with 131I Imaging negative, the sensitivity of 18F-FDG is 79.3%,but in the patients with 131I imaging positive, the sensitivity of 18F-FDG is only 18.6%.
Conclusion
This study with 131I and 18F-FDG in FDG-SPECT further demonstrates the single study of 131I whole body scan or 18F-FDG imaging can not provide a high enough sensitivity for the detection of metastatic
thyroid cancer. But, the combined protocols can get better results for the staging
of thyroid carcinoma with the alternating uptake of 131I and 18F-FDG.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical ImagingAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose.Blood. 1998; 91: 4464-4471
- Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods.Eur J Nucl Med. 2000; : 731-743
- Feasibility of imaging photodynamic injure to tumors by high-resolution positron emission, tomography.Eur J Nucl Med. 1998; 25: 1248-1254
- Functional imaging of endocrine tumors: role of positron emission tomography.Endocr Rev. 2004; 25: 568-580
- PET in the follow-up of differentiated thyroid cancer.Br J Radiol. 2003; 76: 690-695
- [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.J Clin Endocrinol Metab. 1999; 84: 2291-2302
- Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer.J Nucl Med. 1996; 37: 1468-1472
- Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy.J Nucl Med. 2001; 42: 1464-1469
- Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer.Eur J Nucl Med. 1996; 23: 312-319
- Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer.Eur J Nucl Med. 1997; 24: 1342-1348
- Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study.Eur J Nucl Med. 1999; 26: 1547-1552
- Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans.Langenbecks Arch Surg. 1998; 383: 160-163
- Comparison of 18FDG-PET with 131iodine and 99 mTc-sestamibi scintigraphy in differentiated thyroid cancer.Thyroid. 1997; 7: 327-335
- Detection of residual and recurrent thyroid cancer by radionuclide imaging.Thyroid. 1999; 9: 443-446
- Fluorine-18 fluorodeoxyglucose dual-head positron emission tomography in the detection of recurrent differentiated thyroid cancer: preliminary results.Eur J Nucl Med. 1999; 26: 1606-1609
- Is [18F]-2-fluoro-2-deoxy-d-glucose (FDG) scintigraphy with non-dedicated positron emission tomography useful in the diagnostic management of suspected metastatic thyroid carcinoma in patients with no detectable radioiodine uptake?.Eur J Endocrinol. 2003; 149: 293-300
- Value of preoperative diagnostic modalities in patients with recurrent thyroid carcinoma.Surgery. 2000; 128: 1067-1074
- Nuclear medicine in diagnosis, staging and follow-up of thyroid cancer.Q J Nucl Med Imaging. 2004; 48: 82-95
- Initial experience in use of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in thyroid carcinoma patients with elevated serum thyroglobulin but negative iodine-131 whole body scans.Singapore Med J. 2005; 46: 297-301
- Relationship between differentiation and expression of sodium/iodide symporter or glucose transporter-1 in differentiated thyroid carcinoma.J Nucl Med. 2001; 42: 133
- Expression of the Na+/I− symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes.J Clin Endocrinol Metab. 1999; 84: 3228-3234
Article info
Publication history
Published online: November 22, 2007
Accepted:
July 24,
2007
Received:
May 20,
2007
Identification
Copyright
© 2008 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
